-
Cisplatin (CDDP): Optimizing Apoptosis and Resistance Assays
2026-05-09
Cisplatin (CDDP) remains a gold-standard DNA crosslinking agent for cancer research, excelling in apoptosis and chemoresistance studies. This guide details actionable workflows, protocol benchmarks, and troubleshooting strategies to maximize reproducibility and data quality using APExBIO’s trusted Cisplatin.
-
DGLA-Induced Ferroptosis via ACSL4 in AML: Mechanistic Insig
2026-05-08
This study uncovers how exogenous dihomo-γ-linolenic acid (DGLA) triggers ferroptosis in acute myeloid leukemia (AML) cells through ACSL4-mediated lipid metabolic reprogramming. The findings suggest a promising direction for overcoming apoptosis resistance in AML by leveraging ferroptosis as an alternative programmed cell death pathway.
-
O-propargyl-puromycin (OPP) for Precision Protein Synthesis
2026-05-08
O-propargyl-puromycin (OPP) transforms real-time protein synthesis measurement in B cell research, enabling high-resolution detection of nascent polypeptides. With robust click chemistry compatibility, OPP empowers researchers to dissect cellular responses and proteomic dynamics, especially in the context of mitochondrial regulation and adaptive immunity.
-
VEGFC–Macrophage Axis and VEGFR-3 Inhibition in NASH Fibrosi
2026-05-07
This study reveals that targeting hepatocyte-derived VEGFC disrupts macrophage-driven inflammation and fibrosis in NASH, with both naringin and the VEGFR-3 inhibitor SAR131675 showing efficacy in preclinical models. The work clarifies the mechanistic role of VEGFC in the hepatic immune microenvironment and highlights selective VEGFR-3 inhibition as a promising approach for metabolic liver disease research.
-
Pazopanib Hydrochloride: Precision Protocols for Cancer Rese
2026-05-07
Pazopanib Hydrochloride (GW786034) empowers oncology researchers with robust anti-angiogenic and tumor inhibition capabilities across diverse cancer models. This article delivers actionable protocols, troubleshooting strategies, and translational insights grounded in cutting-edge in vitro evaluation to maximize reproducibility and impact.
-
Preclinical Characterization of Anlotinib: Selective VEGFR2
2026-05-06
This study rigorously evaluates anlotinib hydrochloride as a highly selective and potent inhibitor of VEGFR2, demonstrating its robust anti-angiogenic activity in preclinical cancer models. The findings highlight the compound’s superior efficacy and selectivity over existing TKIs, positioning it as a promising candidate for anti-angiogenic cancer research and informing protocols for functional angiogenesis assays.
-
WM-8014: Strategic KAT6A Inhibition for Translational Epigen
2026-05-06
Explore how WM-8014, a nanomolar-potent and selective KAT6A/B inhibitor, is redefining the strategic toolkit for translational researchers. This article blends mechanistic insight, experimental evidence, and strategic guidance—anchored in state-of-the-art CRISPR screening—to illuminate new frontiers in oncogene-induced senescence, cell cycle arrest, and epigenetic drug target discovery.
-
MALAT1/miR-135b-5p/GPNMB Axis Modulates Cell Fate in PD Mode
2026-05-05
Lv et al. (2021) reveal that the long non-coding RNA MALAT1 regulates cell proliferation and apoptosis in Parkinson’s disease cell models via the miR-135b-5p/GPNMB axis. Their mechanistic findings highlight new molecular targets for understanding PD pathogenesis and inform the design of in vitro assays probing neurodegenerative mechanisms.
-
Epidermal Growth Factor: Applied Workflows in 3D Tumor Spher
2026-05-05
Recombinant human EGF is redefining 3D tumor spheroid assays by enabling robust, reproducible assessment of cell proliferation and stemness. Discover data-backed protocols, troubleshooting strategies, and how APExBIO’s validated formulation empowers precision in glioblastoma and mucosal healing research.
-
Lactylation-Driven NSUN2-m5C Axis Fuels Perineural Invasion
2026-05-04
This study uncovers how lactate-induced lysine lactylation of NSUN2 at K692 drives RNA m5C modification, stabilizing pro-invasive transcripts to promote perineural invasion in pancreatic ductal adenocarcinoma (PDAC). Functional and mechanistic experiments establish a metabolic-epigenetic axis linking tumor metabolism to aggressive neural infiltration, offering new intervention targets in PDAC.
-
Tivozanib (AV-951): Redefining In Vitro VEGFR Inhibition Ana
2026-05-04
Explore the advanced applications of Tivozanib (AV-951) as a potent VEGFR inhibitor in oncology research. This article uniquely integrates novel in vitro assay paradigms and practical workflow insights, setting it apart from existing content.
-
Fucoidan’s Multi-Pathway Mechanisms: Beyond Oncology Frontie
2026-05-03
Explore how Fucoidan, a sulfated α-L-fucan, exerts anticancer and immune-modulating effects via multi-pathway targeting. This article uniquely connects mechanistic insights to assay selection and translational potential.
-
In Vitro Metrics for Drug Response: Insights from Schwartz 2
2026-05-02
Schwartz (2022) critically re-examines in vitro methods for evaluating anti-cancer drug responses, distinguishing between relative viability and fractional viability as distinct but often conflated measurements. By clarifying these metrics, the dissertation provides a clearer framework for interpreting how small molecules, such as VEGFR inhibitors, affect both proliferation and cell death in cancer models.
-
Cisplatin (CDDP): Overcoming Chemoresistance in Tumor Models
2026-05-01
Explore how Cisplatin (CDDP) advances cancer research by targeting chemoresistance and tumor stemness. This in-depth analysis reveals new strategies for apoptosis assays and xenograft studies, uniquely bridging assay design with translational oncology.
-
Quizartinib (AC220): Applied FLT3 Inhibition in AML Workflow
2026-05-01
Quizartinib (AC220) stands out as a highly selective FLT3 inhibitor, empowering acute myeloid leukemia (AML) researchers to dissect signaling and resistance with precision in both in vitro and in vivo systems. This article bridges cutting-edge mechanistic studies, protocol optimization, and real-world troubleshooting to maximize data quality and translational insights.